923MO First results from a phase I trial of SNV1521, a next generation, CNS-penetrant, PARP1-selective inhibitor in patients (pts) with molecularly selected advanced solid tumors.
Saved in:
| Title: | 923MO First results from a phase I trial of SNV1521, a next generation, CNS-penetrant, PARP1-selective inhibitor in patients (pts) with molecularly selected advanced solid tumors. |
|---|---|
| Authors: | Yap, T.A.1 (AUTHOR), Lemech, C.2 (AUTHOR), Voskoboynik, M.3 (AUTHOR), Millward, M.4 (AUTHOR), Hafez, M.5 (AUTHOR), Tam, L.6 (AUTHOR), Subbiah, V.7 (AUTHOR), Call, J.A.8 (AUTHOR), Zhou, Y.9 (AUTHOR), Terry, K.10 (AUTHOR), O'Hayer, K.10 (AUTHOR), Lorusso, P.M.11 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS603-S604. 2p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
